79 related articles for article (PubMed ID: 1644865)
21. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP
J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700
[TBL] [Abstract][Full Text] [Related]
22. Stimulation of tissue-type plasminogen activator synthesis by retinoids in cultured human endothelial cells and rat tissues in vivo.
Kooistra T; Opdenberg JP; Toet K; Hendriks HF; van den Hoogen RM; Emeis JJ
Thromb Haemost; 1991 May; 65(5):565-72. PubMed ID: 1908141
[TBL] [Abstract][Full Text] [Related]
23. Butyrate inhibits the retinoic acid-induced differentiation of F9 teratocarcinoma stem cells.
Levine RA; Campisi J; Wang SY; Gudas LJ
Dev Biol; 1984 Oct; 105(2):443-50. PubMed ID: 6090244
[TBL] [Abstract][Full Text] [Related]
24. Molecular analysis of early growth-associated events during the differentiation of F9 cells into embryoid bodies.
Whitman MM; Shen YM; Soprano D; Soprano KJ
Cancer Res; 1990 Jun; 50(11):3193-8. PubMed ID: 2139801
[TBL] [Abstract][Full Text] [Related]
25. Transforming growth factor beta inhibits plasminogen activator (PA) activity and stimulates production of urokinase-type PA, PA inhibitor-1 mRNA, and protein in rat osteoblast-like cells.
Allan EH; Zeheb R; Gelehrter TD; Heaton JH; Fukumoto S; Yee JA; Martin TJ
J Cell Physiol; 1991 Oct; 149(1):34-43. PubMed ID: 1834680
[TBL] [Abstract][Full Text] [Related]
26. Elimination of hydrocortisone from the medium enables tissue plasminogen activator gene expression by normal and immortalized nonmalignant human epithelial cells.
Myöhänen H; Virtanen I; Vaheri A
Biol Chem; 2001 Nov; 382(11):1563-73. PubMed ID: 11767946
[TBL] [Abstract][Full Text] [Related]
27. Synergistic effects of clinically achievable concentrations of 12-O-tetradecanoylphorbol-13-acetate in combination with all-trans retinoic acid, 1alpha,25-dihydroxyvitamin D3, and sodium butyrate on differentiation in HL-60 cells.
Zheng X; Chang RL; Cui XX; Kelly KA; Shih WJ; Lin Y; Strair R; Suh J; Han ZT; Rabson A; Conney AH
Oncol Res; 2000; 12(9-10):419-27. PubMed ID: 11697820
[TBL] [Abstract][Full Text] [Related]
28. Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney.
Sappino AP; Huarte J; Vassalli JD; Belin D
J Clin Invest; 1991 Mar; 87(3):962-70. PubMed ID: 1900311
[TBL] [Abstract][Full Text] [Related]
29. Disruption of the cytoskeleton-extracellular matrix linkage promotes the accumulation of plasminogen activators in F9 derived parietal endoderm.
Snyder RW; Lenburg ME; Seebaum AT; Grabel LB
Differentiation; 1992 Aug; 50(3):153-62. PubMed ID: 1330791
[TBL] [Abstract][Full Text] [Related]
30. Effect of retinoic acid on plasminogen activator expression in human melanoma cells.
Alexander CL; Edward M; MacKie RM
Melanoma Res; 1999 Aug; 9(4):360-7. PubMed ID: 10504054
[TBL] [Abstract][Full Text] [Related]
31. Anti-sense inhibition of tissue plasminogen activator production in differentiated F9 teratocarcinoma cells.
Pecorino LT; Rickles RJ; Strickland S
Dev Biol; 1988 Oct; 129(2):408-16. PubMed ID: 2458288
[TBL] [Abstract][Full Text] [Related]
32. Molecular cloning of complementary DNA to mouse tissue plasminogen activator mRNA and its expression during F9 teratocarcinoma cell differentiation.
Rickles RJ; Darrow AL; Strickland S
J Biol Chem; 1988 Jan; 263(3):1563-9. PubMed ID: 2826484
[TBL] [Abstract][Full Text] [Related]
33. Selection and characterization of F9 teratocarcinoma stem cell mutants with altered responses to retinoic acid.
Wang SY; Gudas LJ
J Biol Chem; 1984 May; 259(9):5899-906. PubMed ID: 6325455
[TBL] [Abstract][Full Text] [Related]
34. Differential expression of fetomodulin and tissue plasminogen activator to characterize parietal endoderm differentiation of F9 embryonal carcinoma cells.
Imada S; Yamaguchi H; Imada M
Dev Biol; 1990 Oct; 141(2):426-30. PubMed ID: 1698671
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms regulating plasminogen activators in transformed retinal ganglion cells.
Rock N; Chintala SK
Exp Eye Res; 2008 Mar; 86(3):492-9. PubMed ID: 18243176
[TBL] [Abstract][Full Text] [Related]
36. Reversible effects of sodium butyrate on the differentiation of F9 embryonal carcinoma cells.
Kosaka M; Nishina Y; Takeda M; Matsumoto K; Nishimune Y
Exp Cell Res; 1991 Jan; 192(1):46-51. PubMed ID: 1898593
[TBL] [Abstract][Full Text] [Related]
37. The kinetics of induction of Hox1.6 and C-jun mRNA during three different ways of inducing differentiation in teratocarcinoma F9 cells.
Iwai SA; Nishina Y; Kosaka M; Sumi T; Doi T; Sakuda M; Nishimune Y
In Vitro Cell Dev Biol Anim; 1995 Jun; 31(6):462-6. PubMed ID: 8589890
[TBL] [Abstract][Full Text] [Related]
38. The expression of plasminogen activators and their inhibitors in cultured human retinal capillary endothelial cells.
Redmill BS; Booth NA; Knott RM; Forrester JV
Biochem Soc Trans; 1996 May; 24(2):206S. PubMed ID: 8736864
[No Abstract] [Full Text] [Related]
39. Retinoic acid inhibits sodium butyrate-induced monocytic differentiation of HL60 cells while synergistically inducing granulocytoid differentiation.
He RY; Breitman TR
Eur J Haematol; 1991 Feb; 46(2):93-100. PubMed ID: 1995327
[TBL] [Abstract][Full Text] [Related]
40. F9 Cells Can be Differentiated toward Two Distinct, Mutually Exclusive Pathways by Retinoic Acid and Sodium Butyrate: (teratocarcinoma/differentiation/retinoic acid/sodium butyrate).
Kosaka M; Takeda M; Matsumoto K; Nishimune Y
Dev Growth Differ; 1994 Apr; 36(2):223-230. PubMed ID: 37281067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
